الفهرس 
Acute lymphoblastic leukemiaOnly 14 pages are availabe for public view
 |  | from | 228 |  |  |
| | | from | 228 | | |
Abstract
Methotrexate (MTX) is an important therapeutic drug in the treatment of
ALL and other malignancies. The effectiveness of MTX is largely
attributable to its role as an inhibitor of dihdrofolate reductase (DHFR). Its
metabolites also inhibit other folate enzymes, including 5,10-
methylenetetrahydrofolate reductase (MTHFR), which converts 5,10-
methylenetetrahydrofolate to 5,1 O-methyltetrahydrofolate (Ulrich et al.,
2001).
Pharmacogenetics represents a new promismg tool for the
individualization of therapy. Several genetic polymorphisms and haplotypes
involved in drug metabolism, transport and mechanism of action have been
investigated as markers for optimizing treatment outcome. The non-
synonymous C677T variants in the 5,1 O-methylenetetrahydrofolate reductase
(MTHFR) gene is among the most studied genetic polymorphisms for
identifying predictors of response to antifolates such as MTX (Rosenblat